14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
UBXG vs ABVX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, U-BX Technology Ltd. (UBXG) is the stronger overall head-to-head candidate over Abivax SA (ABVX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UBXG carries a Unified Composite Score of 48.9/100 (HOLD) at $5.03 (N/M Forward P/E, -87.6% operating margin), whereas ABVX carries 42.4/100 (HOLD) at $73.20 (N/M Forward P/E, -6270.4% operating margin).
Growth vs. Quality Trade-Off: UBXG earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. ABVX 42.4/100 HOLD) and 10.23β · 225% Vol risk profile, whereas ABVX leads top-line expansion (-6.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: UBXG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.9); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UBXG vs ABVX. Trailing 12-month operating profitability (UBXG -87.6% vs ABVX -6270.4%) and valuation multiples (UBXG N/M vs ABVX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $7.1B market capitalization and -6270.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ UBXG vs ABVX Key Questions & Quantitative Answers
As of Nov 20, 2026, U-BX Technology Ltd. (UBXG) is the stronger overall head-to-head candidate over Abivax SA (ABVX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UBXG carries a Unified Composite Score of 48.9/100 (HOLD) at $5.03 (N/M Forward P/E, -87.6% operating margin), whereas ABVX carries 42.4/100 (HOLD) at $73.20 (N/M Forward P/E, -6270.4% operating margin). Growth vs. Quality Trade-Off: UBXG earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. ABVX 42.4/100 HOLD) and 10.23β · 225% Vol risk profile, whereas ABVX leads top-line expansion (-6.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: UBXG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.9); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABVX leads the Growth & Scale pillar: UBXG posts -32.6% YoY revenue growth and -88.4% YoY earnings growth on $24M TTM revenue (0.3% gross margin, -87.6% operating margin), compared with ABVX at -6.8% YoY revenue growth and +0.0% YoY earnings growth on $4.7M TTM revenue (100.0% gross margin, -6270.4% operating margin). On trailing 12-month operating scale, UBXG generates $24M in USD-normalized revenue versus $4.7M for ABVX. In operating R&D and SG&A reinvestment, UBXG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABVX.
UBXG screens cheaper on headline valuation multiples. UBXG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.4x EV/Revenue (-53.4% EBITDA margin), whereas ABVX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UBXG (-46.6% ROE) versus ABVX (-252.3% ROE) capital efficiency.
In options market volatility and institutional positioning, UBXG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (10.23β · 225% Vol realized risk). By comparison, ABVX carries 76.9% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.